Skip to content

Read-only version: For security reasons, the Research Information System (FIS) has been temporarily replaced by this read-only version. All public content and full texts remain available; login, editing, submission and statistics are not available. Questions: fis@uni-bamberg.de

Home › Publications › Health care effects and medical benefits of a smartphone-based diabetes self-management application : study protocol for a randomized controlled trial

Publication

Health care effects and medical benefits of a smartphone-based diabetes self-management application : study protocol for a randomized controlled trial

Ehrmann, Dominic; Eichinger, V.; Vesper, Iris; u. a. (2023): Health care effects and medical benefits of a smartphone-based diabetes self-management application : study protocol for a randomized controlled trial, in: Bamberg: Otto-Friedrich-Universität, S. 1–8.

Details

Faculty/Chair
Faculty/Professorship
Author
ORCID iDEhrmann, Dominic; Eichinger, V.; Vesper, Iris; Kober, J.; Kraus, M.; Schäfer, V.; ORCID iDHermanns, Norbert; Kulzer, Bernhard; Silbermann, Stephan
Publisher Information
Otto-Friedrich-Universität : Bamberg
Year of publication
2023
Source/Other editions
Trials, 23 (2022), 1, 282. - ISSN: 1745-6215
Year of first publication
2022
Language
English
Licence
URN
Abstract

Background:

Diabetes self-management is a mainstay of diabetes care, but the implementation of self-management regimens into daily life is complex and often results in discouragement and distress. Modern approaches such as smartphone-based self-management applications are therefore needed to support people with diabetes. Since reimbursability would increase the availability of such digital applications to people with diabetes, we designed a study that meets all scientific and methodological requirements set by the German Digital Healthcare Act to allow reimbursement for a specific application (mySugr PRO). Here, we report the protocol of this study that aims at evaluating the efficacy of the digital self-management application with regard to patient-reported outcomes and medical benefits.

Methods/design:

This multicenter, open-label, randomized, parallel-group, controlled trial will evaluate the health care effects and medical benefits of mySugr PRO. A total of 466 people with diabetes will be randomly allocated (2:1 randomization) to the interventional group (n = 311) that will use the digital self-management application during the 12-week study period or the control group (n = 155; no usage of the application). Baseline and follow-up examinations will assess diabetes distress as the primary endpoint as well as empowerment, HbA1c, blood glucose data, self-management, general well-being, and treatment satisfaction as secondary endpoints. Statistical analyses will use an intention-to-treat procedure (using multiple imputation for missing values) as well as a per-protocol approach for sensitivity analysis.

Discussion:

To the best of our knowledge, this study will be one of the largest diabetes-specific evaluations of a digital health application supporting people with diabetes in their diabetes self-management that follow the requirements of the German Digital Healthcare Act.

Trial registration:

German Clinical Trial Register DRKS00022923. Registered on 22 October 2020.

GND Keywords
Diabetes mellitus
Selbstmanagementtherapie
E-Health
Keywords
Diabetes
Self-management
Diabetes distress
Digital health application
DDC Classification
150 Psychology
RVK Classification
YC 7200
Peer Reviewed
yes
International Distribution
yes
Open Access Journal
yes
Type
Article
URI
Activation date
2023-10-11

Permalink: https://fis.uni-bamberg.de/handle/uniba/91226 · Data as JSON · Cite: BibTeX · RIS

Data as of: 2026-11-16

Restricted read-only access: login, editing and submission are temporarily disabled.